Provided by Tiger Fintech (Singapore) Pte. Ltd.

SAB Biotherapeutics, Inc.

2.60
+0.09994.00%
Post-market: 2.600.00000.00%19:48 EDT
Volume:70.74K
Turnover:185.93K
Market Cap:24.16M
PE:-0.70
High:2.73
Open:2.44
Low:2.42
Close:2.50
Loading ...
Jul 11, 2022

Major Issues Report

8-K - Current report
Jul 05, 2022

Major Issues Report

8-K - Current report
Jun 07, 2022

Major Issues Report

8-K - Current report
Jun 06, 2022

Major Issues Report

8-K - Current report
May 27, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
May 12, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 29, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 01, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Jan 10, 2022

Major Issues Report

8-K - Current report
Jan 06, 2022

Major Issues Report

8-K - Current report
Dec 13, 2021

Correspondence

CORRESP [Cover] - Correspondence
Dec 03, 2021

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Nov 22, 2021

Major Issues Report

8-K - Current report
Nov 22, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 22, 2021

Major Issues Report

8-K/A [Amend] - Current report
Nov 19, 2021

Major Issues Report

8-K - Current report
Nov 02, 2021

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Nov 01, 2021

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership